Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.
about
Marine algal toxin azaspiracid is an open-state blocker of hERG potassium channelsAnorexia nervosaGender difference in QTc prolongation of people with mental disordersRisk assessment of drug-induced QT prolongationClinical and genetic determinants of torsade de pointes riskRisk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolonesPharmacometabolomic approach to predict QT prolongation in guinea pigsEfavirenz-associated QT prolongation and Torsade de Pointes arrhythmia.QTc prolongation in apheresis platelet donors.Drug-induced Brugada syndrome.Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical SignificanceH1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects.Emerging treatments in the management of schizophrenia - focus on sertindolePharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Drug safety and efficacy evaluation of sertindole for schizophrenia.New Generation Antipsychotic Drugs and QTc Interval Prolongation.Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.Cardiotoxicity and prescription of thioridazine in New Zealand.Antipsychotics and QT prolongation.Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations.Cardiologic side effects of psychotropic drugs.The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.Drug-induced arrhythmia: pharmacogenomic prescribing?Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.Long QT Syndrome Leading to Multiple Cardiac Arrests After Posaconazole Administration in an Immune-Compromised Patient with Sepsis: An Unusual Case ReportSex-specific differences in side effects of psychotropic drugs: genes or gender?Clinically-relevant anticancer-antidepressant drug interactions.Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort.Effects of three fluoroquinolones on QT analysis after standard treatment courses.Iohexol contrast medium induces QT prolongation in amiodarone patients.Registry for torsades de pointes with drug treatment exists.Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation.Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.Olanzapine: a proarrhythmic drug?Antipsychotic induced prolongation of QTc interval treated with magnesium.Predicting drug candidate victims of drug-drug interactions, using microdosing.Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects.
P2860
Q24599453-0BF0DC3D-D851-4D8D-8577-7202AD671765Q24605310-2617C7CD-1B21-44DA-8677-9EE8A5965921Q24800936-C948F04F-0B53-49A4-AA43-005182CB5A8BQ26773356-2B5DA183-FB73-4E72-9721-B2446747F1CBQ27014821-E719A749-305C-4EC1-A7DF-EFDC477F304EQ28345609-9B292C5A-3082-4FD1-BC18-E4ED0494D86CQ28485993-B1625B7A-37D7-4530-A545-221BC56EA46DQ33147714-F9C535F1-7DC3-4912-9F9F-1CD1B7EFDAF8Q33148196-B3F57906-D270-4B47-A25B-1FC87342854EQ33157460-F1D7BC94-E16E-45EA-97F9-767D0CF1DB4AQ33653994-2519FCD8-8E82-4CA2-969E-C55CCDABA45BQ34125185-9D6A5A95-387B-4DAF-9249-6DDF69AA6603Q34129334-23084B56-3C4F-4C6F-A10E-C5441D69AD82Q34274859-CF1DD515-3F6C-4D40-B12D-B00A9FFCD88FQ34300628-D28C6EDC-18B5-4BD4-B19A-A4322F4A70B8Q34319695-FB82CC30-0DDE-4DAF-A78C-379BB6515C9CQ34711627-C66DCC5D-C818-4A79-80C6-13A8AF558AAEQ34778034-391D2655-EACB-4C5A-89B0-FC01ED471CCEQ35048069-C7F68660-5794-402A-882C-78F05823E769Q35212261-EB86D027-CD42-4664-A87F-7A3ADC756BC5Q36077336-04868EB7-D239-4E86-897B-6836F32842ABQ36321595-0EADD6BD-8A8D-4F13-9DFB-868713C74D83Q36512441-DE22BF23-DD19-4857-B3DB-7D5089A84AEDQ36853529-8CDDEA89-CC34-4C23-981D-44604550330BQ36886266-0957391C-9708-4652-BAE3-3CC9829FD91DQ36987981-FADC9F6B-E00C-4BB9-B5E5-E8C6C12DC2C9Q37020761-17EE0318-64F5-4EED-B72E-94B24F076FF6Q37598900-8A512595-7F9D-4B7B-9523-15C779815FF3Q37970709-B014E5AE-70F8-4288-86E8-65132D94365AQ41945547-A26E8CFA-C018-4A80-BD53-F2CCE8416D7FQ42650229-B626A6A5-5E2B-47D7-8246-007C771B291DQ42680174-59D8863F-9DC6-4655-A5A9-1CE53E4BE4F2Q42759695-A8A8226D-4440-4AE2-A853-2809AC0C8416Q42771197-F9F00DC1-391D-4A44-AE83-238F66C9FF0EQ42990255-4A515148-DCCE-4C2F-B034-73EE7BF107A5Q43670022-AA7D0C2D-37DD-4D57-A51D-D64F8F28C624Q44159913-282E91DA-C852-4443-8D01-49D0D3C22E3EQ44599226-23315729-4B99-45CC-88A4-B759DFCAE5F9Q45348533-36CCC056-BFAC-4EB0-A489-2E7121684358Q46587405-2F746E8C-EFA4-4795-8706-44E71FDA282E
P2860
Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Risk of torsades de pointes wi ...... ugs can cause qt prolongation.
@en
Risk of torsades de pointes wi ...... ugs can cause qt prolongation.
@nl
type
label
Risk of torsades de pointes wi ...... ugs can cause qt prolongation.
@en
Risk of torsades de pointes wi ...... ugs can cause qt prolongation.
@nl
prefLabel
Risk of torsades de pointes wi ...... ugs can cause qt prolongation.
@en
Risk of torsades de pointes wi ...... ugs can cause qt prolongation.
@nl
P2860
P1433
P1476
Risk of torsades de pointes wi ...... ugs can cause qt prolongation.
@en
P2860
P304
P356
10.1136/BMJ.320.7243.1158
P407
P577
2000-04-01T00:00:00Z